Colchicine is the least effective cure for COVID

Colchicine is the least effective cure for COVID


The use of colchicine to reduce the complications of COVID-19, touted last year with great fanfare by the Montreal Heart Institute, has just hit another pitfall.

The Research Institute of the McGill University Health Center yesterday published a compilation on the effectiveness of treatments that currently exist to mitigate the impact of COVID-19. < /p>

At the top of the list stands out the long-awaited new drug from Pfizer, Paxlovid, while colchicine ranks last, according to this list compiled by Montreal researchers.

< p>The right choice

The aim of the study is to help doctors make the right choice of treatment. 

“We felt it was important to conduct this study in order to facilitate comparative decision-making concerning the choice of treatment,” the study release reads.

Eight drugs were reviewed by the group of researchers.

The most effective is Paxlovid, approved by Health Canada last Monday, reportedly resulting in one hospitalization avoided for every 24 patients treated, at a cost of $12,720. 

The least useful is colchicine, with one hospitalization averted for 87 patients, at a cost of $3,333.

Second and third are drugs that are almost as effective as Paxlovid, Sotrovimab (one hospitalization avoided for 25 patients) and Remdesivir (one for 28), but which are much more expensive, with treatment costs of $52,000 each.

Evidence of more

This study therefore confirms once again the very limited usefulness of colchicine in the therapeutic arsenal to combat COVID-19.

However, a year ago, the Heart Institute of Montreal announced with great fanfare, following a clinical study, that the use of colchicine constituted a “major scientific discovery” to reduce the symptoms of COVID-19.

A few months later , the final version of the Heart Institute study, reviewed by external experts, was published in the medical journal The Lancet and instead concluded that colchicine was of limited usefulness.< /p>

Note that the McGill University Health Center study does not oppose the use of colchicine against COVID-19. 

However, it should be remembered that the National Institute of Excellence in Health and Social Services, responsible for advising physicians on medications in Quebec, intervened twice to advise against use, last year.

Share Button